Journal
FRONTIERS IN MEDICAL TECHNOLOGY
Volume 3, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmedt.2021.778645
Keywords
oral route; antimicrobial peptides (AMPs); infectiology; pharmaceutical forms; drug delivery systems (DDS)
Categories
Funding
- NANOMED EMJMD - European Union
- Erasmus+ Program by the European Union in the Framework Agreement [2016-2057/001-001 EMJMD, 574439-EPP-1-FR-EPPKA1-JMD-MOB]
Ask authors/readers for more resources
Antimicrobial peptides (AMPs) have the potential to combat antimicrobial resistance, but their oral administration is currently limited. Developing novel drug delivery systems could be a promising way to improve the oral bioavailability of AMPs.
Antimicrobial peptides (AMPs) have a great potential to face the global expansion of antimicrobial resistance (AMR) associated to the development of multidrug-resistant (MDR) pathogens. AMPs are usually composed of 10-50 amino acids with a broad structural diversity and present a range of antimicrobial activities. Unfortunately, even if the oral route is the most convenient one, currently approved therapeutic AMPs are mostly administrated by the intravenous route. Thus, the development of novel drug delivery systems (DDSs) represents a promising opportunity to protect AMPs from chemical and enzymatic degradation through the gastrointestinal tract and to increase intestinal permeability leading to high bioavailability. In this review, the classification and properties as well as mechanisms of the AMPs used in infectiology are first described. Then, the different pharmaceutical forms existing in the market for oral administration are presented. Finally, the formulation technologies, including microparticle- and nanoparticle-based DDSs, used to improve the oral bioavailability of AMPs are reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available